BiotechTube

CHIKV VLP/adjuvant + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chikungunya Virus

Conditions

Chikungunya Virus

Trial Timeline

May 12, 2022 → Aug 8, 2023

NCT ID
NCT05349617

About CHIKV VLP/adjuvant + Placebo

CHIKV VLP/adjuvant + Placebo is a phase 3 stage product being developed by Bavarian Nordic for Chikungunya Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT05349617. Target conditions include Chikungunya Virus.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT05349617Phase 3Completed
NCT05072080Phase 3Completed

Competing Products

20 competing products in Chikungunya Virus

See all competitors
ProductCompanyStageHype Score
CHIKV VLP/unadjuvanted + CHIKV VLP/adjuvanted + PlaceboBavarian NordicPhase 2
49
ChikungunyaBavarian NordicPhase 2
49
CHIKV VLP vaccine booster + Placebo boosterBavarian NordicPhase 3
74
CHIKV VLP/adjuvant + PlaceboBavarian NordicPhase 3
74
CHIKV VLP, adjuvantedBavarian NordicPhase 2
49
CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3
74
CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3
74
Live-attenuated CHIKV vaccine VLA1553Valneva SEPre-clinical
18
VLA1553Valneva SEPhase 3
72
Live-attenuated CHIKV vaccine VLA1553Valneva SEPre-clinical
18
Biological Vaccine VLA1553Valneva SEPhase 3
72
VLA1553 full dose + VLA1553 half dose + ControlValneva SEPhase 2
47
Active + PlaceboValneva SEPhase 3
72
Live-attenuated CHIKV vaccine VLA1553 + Vaccine(s) approved for use during pregnancy by the MoHValneva SEPre-clinical
18
VLA1553Valneva SEPhase 3
72
VLA1553 + ControlValneva SEPhase 3
72
VLA1553 + PlaceboValneva SEPhase 3
72
VLA1553Valneva SEPhase 1
28
Live-attenuated CHIKV vaccine VLA1553Valneva SEPre-clinical
18
INTERCEPT PlateletsCerusPre-clinical
15

Other Products from Bavarian Nordic

IMVAMUNE®Approved
82
VAXCHORA (Cholera Vaccine, Live, Oral)Approved
82
PROSTVAC-V + PROSTVAC-F + GM-CSF + PlaceboPhase 3
74
PXVX0200 + placeboPhase 3
74
MVA-BN standard regimen + MVA-BN standard regimen (Administered as PEP)Phase 3
74